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Background: Viral pathogens were more commonly reported than previously estimated in community-acquired
pneumonia (CAP) patients. However, the real role of virus was still controversial.
Methods: Consecutive adult patients with CAP between April and December, 2009 were prospectively enrolled.
A four-fold or greater increase of IgG-titres against respiratory viruses in pair sera was tested by means of
hemagglutination inhibition assay or indirect immunofluorescence. Swab samples were tested by cell culture and/
or nucleic amplification tests. Viral etiology was considered definitive if at least one of the above tests was positive.
Results: Viral etiology was established in fifty-two (34.9%) of 149 CAP patients, twenty-two (81.5%) of 27 influenza
like illness patients, and none of 75 volunteer controls. Forty-seven CAP patients were infected by a single virus (24
influenza A virus, 5 influenza B, 10 parainfluenza virus type 3 [PIV-3], 2 PIV-1, 2 adenovirus, 2 human rhinovirus and 2
coronavirus OC43), five cases by two or three viruses co-infection. Fever ≥ 39°C (66.7%), fatigue (64.6%), and purulent
sputum (52.1%) was the most common symptoms in viral pneumonia patients. On multivariate analysis, myalgia
was included in the model for pneumonia associated with influenza infection. In the CURB-65 model only influenza
infection was found independently associated with severe disease (CURB-65 score ≥ 3) out of variables, including
age(years), sex, current smoking status, sick contact with febrile patients, numbers of comorbidity, presence of
influenza infection, presence of PIV infection, with P = 0.021, OR 7.86 (95% CI 1.37-45.04).
Conclusion: Respiratory virus was not a bystander, but pathogenic in pneumonia and was a common cause of
CAP.
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In China, pneumonia ranks fifth among all causes of
death in humans. However, there are limited data re-
garding the etiology of community-acquired pneumonia
(CAP) worldwide and in China, with about 17% to 48%
unknown [1]. This may lead to inappropriate antimicro-
bial therapy and emergence of drug-resistant bacteria.* Correspondence: chenrc@vip.163.com
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unless otherwise stated.Since influenza virus was first isolated in ferrets from
pneumonia patients in 1933 by Smith [2], viral etiology
of pneumonia has attracted more and more attention.
Recently, our ability to detect viral pathogens has dra-
matically improved after the introduction of highly sen-
sitive nucleic amplification tests (NATs). Additionally,
NATs has its superiority in detection of viruses that are
difficult to grow in cell culture, such as human rhino-
virus (HRV), human coronaviruses (HCoV), and new
emerging pathogens human metapneumovirus (hMPV)
and human bocavirus (HBoV).
Recently epidemiological surveys on etiology of CAP
showed that respiratory viruses accounted for 15% totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The CreativeCommons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pneumonia was few studied and still controversial [3,6].
It may partially due to poor sensitivity of most viral test-
ing assays (except NATs). However, it was difficult to
confirm the pathogenicity of virus tested by NATs. Thus,
clinical features of specific viral pneumonia were not
well described [4,5,7]. After combined the improvement
in sensitivity and specificity of viral testing assay with
more comprehensive design study, more valuable infor-
mation will be available.
Moreover, because there is limited information concern-
ing to the prevalence and clinical features of viral pneu-
monia, guideline of diagnosis and treatment of CAP does
not provide much recommendation about the assessment
and management of viral CAP.
In order to better understand the real role of respira-
tory virus in pneumonia and better manage the patients,
we conducted a prospective observational study to reveal
the viral etiology of adult CAP in Guangzhou, as com-
pared with etiology of patients diagnosed with influenza
like illness (ILI) and with volunteer controls.
Methods
Patients
Between April and December, 2009, consecutive adult pa-
tients admitted to the First Affiliated Hospital of Guangzhou
Medical University and diagnosed with CAP within 14 days
from onset were studied. They were sampled for throat
swabs at enrollment and paired sera by at least two weeks
interval. CAP was defined as the presence of a new infiltrate
on the chest radiographs, together with a new cough or spu-
tum or change in respiratory symptoms, or fever, or sign of
consolidation of lung or rales, or leukocytosis (>10 × 109/L)
or leucopenia (<4 × 109/L) [8]. No alternative diagnosis was
responsible to the new infiltrate during follow-up. Exclusion
criteria was: 1) immunosuppression (e.g. human immuno-
deficiency virus infection); 2) previous organ transplantation;
3) immunosuppressive therapy, defined as daily doses
20 mg prednisolone or equivalent for 2 weeks; 4) any dose
of an immunosuppressive combination regimen, in-
cluding azathioprine, cyclosporin and/or cyclophosphamide;
5) treating cancer; 6) lung abscess, aspiration pneumonia
and tuberculosis. Pregnant women, patients who were re-
leased from hospital within 14 days and who didn’t signa-
ture the consent were excluded.
Additionally, ILI patients were enrolled. It was defined
as an acute illness within 14 days, with fever (≥38°C),
two constitutional symptoms (chills, headache, myalgia
or fatigue) and one respiratory symptom (cough, sore
throat or coryza) [9], without evidence of pneumonia. Throat
swab samples were taken at enrollment and paired sera
were taken by two weeks interval.
Both pneumonia patients and ILI patients were followed
up via telephone or interview for up to 30 days. All datawere recorded by a trained doctor, who was blinded to the
results of viral detection.
Moreover, volunteer controls without clues of acute ill-
nesses within one month were also enrolled and sampled
for throat swabs.
The study was approved by the ethics committee of The
First Affiliated Hospital of Guangzhou Medical University
and informed consent was obtained for all subjects.
Viral testing
Paired sera were routinely performed by hemagglutination
inhibition assay [10] for detection of seasonal influenza
virus type A and B (Flu A and B) and pandemic (H1N1)
2009 influenza A virus (A[H1N1]pdm09), indirect im-
munofluorescence (EUROIMMUN, Lübeck, German) for
detection of parainfluenza virus type 1, 2, 3 and 4 (PIV-
1,2,3,4), adenovirus (Adv) and respiratory syncytial virus
(RSV). Four-fold or greater increase of IgG-titres was de-
fined as positive. Swab samples were processed for study
of viruses mentioned above through isolation of viruses
in shell-vial cell culture system (PIV-4 is excluded)
and for detection of nucleic acids by reverse transcription
polymerase chain reaction (RT-PCR) assays (PIV-2 and
PIV-4 is excluded) [11-13]. Swab samples were also tested
for HRV 1/2/3/4, HCoV (229E, OC43, NL63, HKU1),
hMPV and HBoV by Taqman real-time RT-PCR (rRT-
PCR) [14], in accordance with the manufacturer’s protocol
(Guangzhou HuYanSuo Medical Technology Co., Ltd,
China). Viral etiology was considered definitive if at least
one of the above tests was positive.
Statistical analysis
Statistical software (SPSS 13.0; SPSS, Chicago, IL, USA)
was employed for statistical analysis. Quantitative data
were presented as median and interquartile range (IQR)
and compared by non-parametric Kruskal-Wallis test.
The categorical variables were reported as frequencies
and percentages and compared using the Fisher’s exact
or Chi-square test.
Logistic regression analysis was applied to test whether
or not certain clinical features on admission were associ-
ated with specific virus infection. The presence or ab-
sence of specific virus infection was analysed. The other
variables included age (years), sex, current smoking sta-
tus, sick contact with febrile patients, numbers of co-
morbidity, presence of fever ≥ 39°C, myalgia, headache,
fatigue, dry cough, coryza, sore throat, hemoptysis, chest
tightness or pain, dyspnea, and the presence of neutrophi-
lia (defined as >8 × 109/L), leukocytosis (defined as >10 ×
109/L) and lymphopenia (defined as <0.8 × 109/L).
Logistic regression analysis was also applied to test
whether demographic features or specific virus infection
were associated with severe disease, which was defined
as CURB-65 score equal or greater than 3 at admission.
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sion of new onset, blood urea nitrogen greater than
7 mmol/l, respiratory rate of 30 breaths per minute or
greater, systolic blood pressure less than 90 mmHg or
diastolic blood pressure less than 60 mmHg, age 65 or
older. Each risk factor scores one point, for a maximum
score of 5.The other variables included in the model
were: age (years), sex, current smoking status, sick con-
tact with febrile patients, numbers of comorbidity, pres-
ence of influenza infection, presence of PIV infection.
For all logistic regression analysis, variables with a
P value < 0.1 in binary analysis were entered in the multi-
variate analysis. The level of significance was set at <0.05.
Results
Overall, 261 individuals were enrolled, including 159
cases of CAP, 27 cases of ILI and 75 cases of volunteer.
However, 10 cases of CAP were excluded (2 obstructive
pneumonia, 3 pulmonary tuberculosis, 4 immunosup-
pressed patients and 1 sheep brucellosis). Eighty-nine
patients had at least one underlying condition (Table 1).
Swab samples were available in all patients and volun-
teers, paired sera in 70 cases of CAP patients and in all
ILI patients.
Viral etiology was established in 52 (34.9%) of 149
CAP patients, in 22 (81.5%) of 27 ILI patients, as shown
in Table 2. All volunteers were virus negative. Among 58
viruses from CAP patients, 18 viruses were detected by
shell-vial cell culture system, 47 viruses by NATs and 20
viruses by serological survey, respectively (Figure 1).
Sputum bacterial culture was performed for the clinical
need in 77 hospitalized patients with CAP and results was
also recorded. Six patients yield a positive result (Table 2).
Three out of six patients were virus positive.Table 1 Demographic data and comorbidity of patients and v
CAP
Cases 149












Note: *All data were showed as numbers (%) unless otherwise specified. †Comparis
Kruskal-Wallis test for quantitative characteristics and Fisher’s exact or Chi-square teClinical features and severity of illness in CAP patients
were summarized in Table 3 and Table 4, respectively. Some
Flu A or PIV-3 infected patients manifested hemoptysis
and chest pain. Dyspnea and gastrointestinal symptoms
were also common in Flu and PIV-3 positive CAP pa-
tients. Compared with virus negative patients, sorethroat
and fatigue was more common, leukocytosis and neu-
trophilia was less common in viral pneumonia patients,
although fatigue and neutrophilia had no statistical sig-
nificance. It seemed that length of hospital stay was lon-
ger, intensive care requirement and 30-day mortality was
higher in virus positive patients, however, there was no
statistical significance. Table 5 showed the significant
features associated with viral pneumonia or severe disease
on multivariate analysis. On viral pneumonia model,
leukocytosis was negative correlated with any virus infec-
tion. While, myalgia was included in the model for pneu-
monia associated with influenza infection. In the CURB-65
model, only influenza infection was found independ-
ently associated with severe disease (CURB-65 score ≥ 3),
with P = 0.021, Odds Ratio (OR) 7.86 (95% Confidence
interval [CI] 1.37-45.04).
All CAP patients received antibiotics. However, few pa-
tients were prescribed for antiviral agents such as oselta-
mivir or zanamivir by clinician. Seven patients (two of
which was virus positive) received short course of intra-
venous ribavirin before their admission to our hospital.
Only one A(H1N1)pdm09 infected patient received oral
oseltamivir before and during his hospitalization in our
hospital. Finally, all but five CAP patients recovered dur-
ing our one month observation. Clinical course of four
CAP patients (one was Flu B positive, one was PIV-3 posi-
tive, none received antiviral drugs) went deteriorated.
They denied going on hospital stay and died within 30 daysolunteer controls
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Figure 1 Number of viruses in community-acquired pneumonia
patients detected by three different assays respectively. (NATs:
Nucleic amplification tests).
Table 2 Etiology of community acquired pneumonia and
influenza like illness
Pathogens Cases Percentage (%)
CAP patients 149
Pure virus infection 49 30.2
Flu A 23 15.4




HCoV OC43 2 1.3
HRV 2 1.3
Flu A + PIV-1 1 0.7
Flu B + PIV-3 1 0.7
PIV-3+ HCoV OC43 1 0.7
Flu A + PIV-3 + HCoV OC43 1 0.7
Virus and bacteria co-infection 3 2.0
Flu A + Escherichia coli 1 0.7
Flu A + ADV + Escherichia coli 1 0.7
PIV-3+ Haemophilus parainfluenzae 1 0.7
Pure bacteria infection 3 2.0
Haemophilus influenzae 1 0.7
Haemophilus hemolyticus 1 0.7
Stenotrophomonas maltophilia 1 0.7
ILI patients 27
Flu A 14 51.9
Flu B 4 18.5
PIV3 1 3.7
Flu A + Flu B 2 7.4
Flu A + PIV1 1 3.7
Flu A + PIV3 1 3.7
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nosed with seasonal influenza A pneumonia, developed re-
spiratory failure and denied invasive ventilation and ICU
admission. Ultimately, he died.
Discussion
Three methodological aspects, including full sets of viral
tests applied, immunocompetent patients enrolled, and
two control groups, made our study different from pre-
vious published data [3-5,15-17]. Base on our methodo-
logical design, finally, we found that virus detected in
pneumonia was not a bystander, but pathogenic. Re-
spiratory virus accounted for about one-third of patho-
gens in CAP. Hence, it was a common cause of CAP. In
view of high prevalence of viral CAP, there was an ur-
gent need to consider routine laboratory detection in
hospitalized CAP patients for an adequate diagnosis of
respiratory viruses. In addition, considering positive cor-
relation between influenza infection and severe disease,
we recommended testing for influenza virus routinely in
severe individuals, especially during the active period of
influenza activity.
Virus in pneumonia may be a bystander, but not patho-
genic. In Johnstone’s and de Roux’s reports, though aeti-
ology of nonimmunocompromised CAP patients were
reported, the real role of virus was not determined [5,16].
Whether samples obtained from upper respiratory tract
can really mirror the true situation occurred in the lower
respiratory tract and lung, it needs to be further studied.
Hence, two control groups were introduced in the present
study to answer this question. One of the purposes of en-
rolment of these two control groups was to describe in-
apparent infection in volunteer individuals without clues
of acute respiratory illness within one month and a higher
rate of viral infection in ILI patients. Another question
was that the extreme sensitivity of the NATs was thought
to be due to false-positive previously. Then, volunteer
controls in our study turned to be virus negative, just what
we expected. Comparison of positive rate of virus between
two control groups and CAP patients in our study re-
vealed that false positive of NATs did not appeared in our
study. Second, in both ILI and pneumonia patients, sero-
conversion of IgG did not happen in all viral positive
patients. Similarly, in report by Gencay, seroconversion of
IgG was found only in 41% of patients diagnosed with
lower respiratory tract viral infection [18]. Hence, even if
four-fold elevation of virus specific antibody titer did not
appear, the positive results from NATs were deemed to be
the pathogen of current pneumonia. Similar to Jennings’s
finding [3], positive results of virus by NATs in CAP should
be considered as the pathogens.
In our study, viral CAP was more common than other
reports worldwide [3-5,7,15,16,19-21]. We speculated that
it may directly manifest the real incidence of viral infection
Table 3 Clinical characteristics of community acquired pneumonia patients with different etiology
Flu A Flu B ADV PIV-1 PIV-3 Rhv HCoV OC43 Dual-virus Virus positive Virus negative P values**
Cases 24 5 2 2 10 2 2 5 52 97
Demographic data
Age (Median [IQR], yrs) 74(32–80) 47(36–73) 21(20–23) 72(65–78) 63(40–70) 72(66–77) 71(67–74) 59(45–65) 62(32–79) 60(36–75) 0.961
Male/Female 15/9 3/2 1/1 2/0 3/7 2/0 0/2 3/1 29/23 55/42 0.913
Sick contact* 5(20.8) 1(20.0) 0 0 1(10.0) 0 0 2(40.0) 9(17.3) 10(10.3) 0.222
Current smoking 3(12.5) 1(20.0) 0 0 2(20.0) 0 0 1(25.0) 7(13.5) 19(19.6) 0.348
Clinical symptoms
Fever ≥ 39°C 14(58.3) 3(60.0) 2(100) 1(50.0) 6(60.0) 1(50.0) 0 4(80.0) 31(59.6) 49(50.5) 0.288
Headache 8(33.3) 3(60.0) 1(50.0) 0 9(90.0) 1(50.0) 0 3(60.0) 25(48.1) 47(48.5) 0.965
Mylgia 10(41.7) 3(60.0) 1(50.0) 0 0 0 0 3(60.0) 17(32.7) 33(34.0) 0.870
Fatigue 14(58.3) 4(80.0) 1(50.0) 1(50.0) 8(80.0) 1(50.0) 0 3(60.0) 32(61.5) 46(47.4) 0.100
Coryza 10(41.7) 2(40.0) 1(50.0) 0 4(40.0) 1(50.0) 0 3(60.0) 21(40.4) 28(28.9) 0.154
Sore throat 10(41.7) 2(40.0) 2(100.0) 0 4(40.0) 2(100) 1(50.0) 4(80.0) 25(48.1) 30(30.9) 0.038
Dry cough 2(8.3) 1(20.0) 1(50.0) 0 0 0 0 0 4(7.7) 9(9.3) 0.982
Purulent sputum 12(50.0) 2(40.0) 1(50.0) 1(50.0) 5(50.0) 1(50.0) 0 4(80.0) 26(50.0) 49(50.5) 0.777
Hemoptysis 2(8.3) 0 0 0 2(20.0) 0 0 0 4(7.7) 3(3.1) 0.391
Chest tightness or pain 6(25.0) 0 0 0 1(10.0) 2(100) 1(50.0) 0 10(19.2) 22(22.7) 0.625
Dyspnea 12(50.0) 3(60.0) 0 1(50.0) 4(40.0) 0 1(50.0) 0 21(40.4) 33(34.0) 0.441
Gastrointestinal symptoms 5(20.8) 1(20.0) 0 0 1(10.0) 1(50.0) 0 1(20) 9(17.3) 15(15.5) 0.770
Laboratory results
Leukocytosis† 8(33.3) 0 1(50.0) 1(50.0) 1(10.0) 1(50.0) 1(50.0) 0 13(25.0) 43(44.8) 0.020
Neutrophilia§ 8(33.3) 0 1(50.0) 1(50.0) 1(10.0) 1(50.0) 1(50.0) 0 13(25.0) 39(40.6) 0.063
Lymphopenia‡ 6(25.0) 0 0 1(50.0) 1(10.0) 0 0 0 7(13.5) 9(9.4) 0.432
ESR > 20 mm/h|| 9(81.8) NA 0 1(100.0) 4(80.0) 1(100) 1(100) 2(66.6) 18(78.3) 45(83.3) 0.597
PaO2 < 80 mmHg|| 10(41.7) 2(40.0) 1(50.0) 1(50.0) 3(75.0) 2(100) 1(50.0) 1(50.0) 21(67.7) 26(61.9) 0.607
Note: *All data were showed as numbers (%) unless otherwise specified. †Leukocytosis was defined as leukocyte count >10 × 109/L. §Neutrophilia was defined as neutrophil count >8 × 109/L. ‡Lymphopenia was
defined as lymphocyte count <0.8 × 109/L. ||Data were available only in some patients. **Comparisons were made between virus positive patients and virus negative patients by non-parametric Kruskal-Wallis test for
quantitative characteristics and Fisher’s exact or Chi-square test for categorical variables, respectively. NA: Data is not available. ESR: erythrocyte sedimentation rate. Gastrointestinal symptoms included nausea,




















Table 4 Severity of illness in community acquired pneumonia patients with different etiology
Flu A Flu B ADV PIV-1 PIV-3 Rhv HCoV OC43 Dual-virus Virus positive Virus negative P values†
Cases 24 5 2 2 10 2 2 5 52 97
Hospitalization§* 21(87.5) 4(80.0) 1(50.0) 2(100) 8(80.0) 2(100) 2(100) 4(80.0) 42(80.8) 76(78.4) 0.729
Length of hospital stay (Median [IQR], days) 11(9–18) 13.5(9–17) 21 12(9.5-14.5) 10.5(6–12.8) 11(13–15) 19(18.5-19.5) 10(8.5-12.8) 11(8.8-17.3) 10(7.8-15) 0.268
Ventilation 2(8.3) 1(20.0) 0 0 0 0 0 0 3(5.8) 3(3.1) 0.722
Intensive care requirement 2(8.3) 1(20.0) 0 0 1(10.0) 0 0 0 4(7.7) 5(5.2) 0.720
ICU admission 1(4.2) 0 0 0 0 0 0 0 1(1.9) 3(3.1) 0.912
30-days mortality 1(4.2) 1(20.0) 0 0 1(10.0) 0 0 0 3(5.7) 2(2.1) 0.343
Note: *All data were showed as numbers (%) unless otherwise specified. †Comparisons were made between virus positive patients and virus negative patients by non-parametric Kruskal-Wallis test for quantitative




















Table 5 Significant features associated with viral
pneumonia or severe disease (CURB-65 score equal or
greater than 3) on multivariate analysis
Etiology Clinical features OR (95% CI) P value
Viral pneumonia
model
Any virus infection Leukocytosis 0.40 (0.19 to 0.85) 0.016
Influenza infection Myalgia 2.27 (1.03 to 5.01) 0.042
PIV infection Myalgia 0.14 (0.03 to 0.67) 0.014
Fatigue 4.38 (1.25 to 15.23) 0.020
Leukocytosis 0.18 (0.04 to 0.86) 0.032
CURB-65 model Influenza infection 7.86 (1.37 to 45.04) 0.021
Note: Leukocytosis was defined as leukocyte count >10 × 109/L.
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on our methodological aspects mentioned above. How-
ever, there were 12 A(H1N1)pdm09, and influenza virus
accounted for two-thirds of viral pathogens in CAP in our
study. Hence, higher prevalence of viral CAP might be
partially influenced by A(H1N1)pdm09 pandemic [22]. In
addition, comprehensive viral testing methods and viral
pathogens improved yields of virus and also contributed
to a higher proportion of viral pneumonia.
In our cohort, Flu A and PIV-3 was the most common
virus of CAP. Viral pattern was similar to the local influ-
enza activity [23]. Similarly, influenza virus was shown
to be predominant viral pathogen in CAP in Spain
[5,16], in patients with acute exacerbations of COPD
and concomitant pneumonia in Hongkong [24], while in
New Zealand, rhinovirus was the most commonly identi-
fied pathogen, followed by influenza virus and RSV [3].
Difference in the prevalence of specific virus infection
among studies may relate to diverse geographical, cli-
mate, activity of the virus pandemic in the community
locally, testing assays applied and the viral pattern stud-
ied, etc.
Likewise, clinical features varied among studies. Jennings
in New Zealand reported that the presence of myalgia
was associated with pneumonia caused by any respira-
tory virus and influenza pneumonia [3]. The presence
of chest pain and leukocytosis had been found to be
far less common in those patients with a viral infec-
tion than in those with a bacterial infection [4,5]. It was
similar in our study that leukocytosis was less common in
virus infected patients, when compared to viral negative
patients. While, Roux demonstrated that chronic heart
failure and the absence of expectoration was associ-
ated with pure viral pneumonia when comparing to
pneumococcal CAP [16]. However, although several vari-
ables were associated with some types of pathogen, clin-
ical characteristics were unable to reliably distinguish
viral pneumonia from viral negative pneumonia or bac-
teria pneumonia. All of these differences were clinicallyinsignificant unless combined with the detection of vi-
ruses. It should be noted that all of the differences identi-
fied in the clinical characteristics among studies, may
also be related to diverse geographical, cultural, and
healthcare environments, though, this has not been con-
firmed [25].
Majority of viral pneumonia patients in our study re-
covered from illness without the aid of antiviral agents,
which was similar to the clinical course of upper respira-
tory tract viral infections. Viral pneumonia seemed to be
a self-limited illness. However, one influenza pneumonia
patients in our study died, because of worsen of comor-
bidity. Also, clinical course of other two patients with
viral pneumonia went deteriorated and died after dis-
charge from hospital. However, illness in virus positive
patients was similar to virus negative patients in length
of hospital stay, intensive care requirement and 30-day
mortality. Hence, one of our puzzled questions remained
that among viral pneumonia patients, who needed to be
treated with antiviral agents? Until now, only influenza
can be effectively treated with neuraminidase inhibitors.
Obviously, considering the high prevalence of viral CAP
in Guangzhou and influenza infection as an independent
variable in the severe disease model, routine laboratory
detection should be taken in hospitalized CAP patients
at admission for an adequate diagnosis of respiratory vi-
ruses, especially influenza virus in severe individuals. Then
they may be benefited from antiviral treatment, if the lat-
ter was conducted in early stage [26].
Another question was that did all patients with viral
community-acquired pneumonia, especially those with-
out evidence of bacteria infection, need to be treated
with antibiotics? Plenty of evidences had shown that
virus infection predisposes the respiratory tract to super-
infection by another pathogen, with bacteria the most
common [27-29]. However, they were not benefited from
preventive prescription of antibiotics [30]. Antibiotics in
these patients had been reported to lead to the occur-
rence of antibiotic resistance in clinically relevant bac-
teria [31]. In our study, three pneumonia patients had
virus and bacteria co-infection. They were not treated
with any antiviral drug. With the “aid” of antibiotics,
they recovered from illness. There was not enough infor-
mation to illustrate the real role of antibiotics in the
treatment of viral pneumonia in our study yet. Hence,
further randomised placebo-controlled trials of anti-
biotic treatment for adult viral pneumonia, similar to
that in the paediatrics [32], is needed to help answer
the question.
Still, there were several limitations in this study. First,
only swab sample was tested for viral culture and NATs.
Increasing the sample types, such as nasopharyngeal as-
pirates, bronchoalveolar lavage fluid and sputum, may
improve the yield of virus. Although multiple methods
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the prevalence of respiratory virus infection and other
types of pathogens. Hence, viral negative patients could
not be ruled out from other viruses’ infection, which was
outside the scope of testing in our study. Second, bac-
teria and atypical pathogens were not studied. Hence,
comparisons of clinical characteristics were only made
between virus positive patients and virus negative pa-
tients. Finally, only three seasons were covered in our
study. A longer time that lasted two or more years and
more patients enrolled may provide us more useful in-
formation. However, further work is ongoing to describe
the epidemiological and clinical characteristics of viral
CAP deeply.
Conclusion
Respiratory virus was not a bystander, but pathogenic in
pneumonia. It was a common cause of CAP. We recom-
mended testing for influenza virus routinely in severe in-
dividuals, especially during the active period of influenza
activity.
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